ABVC vs. DRRX, LEXX, ACXP, XLO, EYEN, VYNE, FBIO, MRKR, LPCN, and CARA
Should you be buying ABVC BioPharma stock or one of its competitors? The main competitors of ABVC BioPharma include DURECT (DRRX), Lexaria Bioscience (LEXX), Acurx Pharmaceuticals (ACXP), Xilio Therapeutics (XLO), Eyenovia (EYEN), VYNE Therapeutics (VYNE), Fortress Biotech (FBIO), Marker Therapeutics (MRKR), Lipocine (LPCN), and Cara Therapeutics (CARA). These companies are all part of the "pharmaceutical preparations" industry.
ABVC BioPharma (NASDAQ:ABVC) and DURECT (NASDAQ:DRRX) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, media sentiment, profitability, earnings, valuation and community ranking.
11.4% of ABVC BioPharma shares are owned by institutional investors. Comparatively, 28.0% of DURECT shares are owned by institutional investors. 11.9% of ABVC BioPharma shares are owned by insiders. Comparatively, 4.3% of DURECT shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
ABVC BioPharma has higher earnings, but lower revenue than DURECT. DURECT is trading at a lower price-to-earnings ratio than ABVC BioPharma, indicating that it is currently the more affordable of the two stocks.
In the previous week, ABVC BioPharma had 1 more articles in the media than DURECT. MarketBeat recorded 2 mentions for ABVC BioPharma and 1 mentions for DURECT. DURECT's average media sentiment score of 1.26 beat ABVC BioPharma's score of 0.95 indicating that DURECT is being referred to more favorably in the news media.
ABVC BioPharma has a beta of 0.75, meaning that its share price is 25% less volatile than the S&P 500. Comparatively, DURECT has a beta of 0.94, meaning that its share price is 6% less volatile than the S&P 500.
DURECT received 316 more outperform votes than ABVC BioPharma when rated by MarketBeat users.
DURECT has a net margin of -279.77% compared to ABVC BioPharma's net margin of -50,504.00%. ABVC BioPharma's return on equity of -207.72% beat DURECT's return on equity.
DURECT has a consensus price target of $27.50, indicating a potential upside of 1,508.19%. Given DURECT's higher probable upside, analysts clearly believe DURECT is more favorable than ABVC BioPharma.
Summary
DURECT beats ABVC BioPharma on 10 of the 16 factors compared between the two stocks.
Get ABVC BioPharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for ABVC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ABVC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ABVC BioPharma Competitors List
Related Companies and Tools
